Slingshot members are tracking this event:
Lannett (LCI) Receives FDA Approval for Buprenorphine and Naloxone Sublingual Tablets in Treatment of Opioid Addiction
Slingshot Insights Explained
Sep 20, 2016
Don’t see a project related to the catalyst you care about?
Related Keywords Fda Approval, Buprenorphine, Naloxone, Sublingual Tablets, Opioid Addiction